Intuitive Surgical, Inc. is a leading healthcare company specializing in robotic-assisted surgery through its flagship da Vinci system, which has established a durable competitive moat with approximately 10,000 systems installed globally and nearly 17 million procedures performed by the end of 2024. The company benefits from a high-quality business model characterized by 85% recurring revenue, strong gross margins of 66.3%, and consistent revenue growth of 23% in the most recent quarter. Despite trading at premium multiples such as a trailing P/E of 53.76 and P/FCF of 64.35, the stock is currently fairly valued relative to its five-year history with a fair value estimate of $1039.74, implying a 130.4% upside. Intuitive Surgical's leadership transition to CEO Dave Rosa continues a legacy of long-tenured management, supporting ongoing innovation and global expansion. The company faces margin pressures from tariffs and regulatory challenges but maintains robust free cash flow generation and a strong growth outlook driven by the adoption of the da Vinci 5 system and expanding procedure volumes.
Intuitive Surgical trades at premium multiples due to its high-quality compounder profile with 85% recurring revenue and strong free cash flow generation. The P/E of 53.76 and P/FCF of 64.35 reflect market expectations for sustained high growth and innovation, particularly driven by the da Vinci 5 system adoption. Analyst sentiment is strongly positive with a consensus rating of Strong Buy, although no specific price targets are provided. The valuation is supported by 21% revenue growth in FY 2025 and a 15% CAGR over the past decade, justifying the premium despite some margin pressures from tariffs and regulatory factors.
12–18 Month Outlook
In 18 months, Intuitive Surgical is expected to continue scaling revenue driven by da Vinci 5 adoption and procedure volume growth, with consensus projecting 14.6% revenue growth to $11.54 billion in 2026 and free cash flow increasing by over 60%. However, margin pressures from tariffs and regulatory challenges may persist, and competitive risks in China could temper upside. The stock's premium valuation implies sensitivity to execution risks despite strong fundamentals.
Bull vs Bear
Bull Case
The da Vinci system maintains a dominant position with over 60% market share in robotic-assisted surgery and nearly 17 million procedures performed globally, supporting recurring revenue growth.
Revenue grew 21% year-over-year in FY 2025, driven by strong adoption of the da Vinci 5 system and a 14-18% increase in procedure volumes, indicating robust demand.
The company benefits from high gross margins of 66.3% and operating margins of 30.5%, reflecting operational efficiency and pricing power.
Free cash flow per share of $6.87 and a projected 62.1% increase in free cash flow to $4.04 billion in 2026 support strong capital allocation capacity.
Long-tenured leadership with CEO Dave Rosa and Executive Chair Gary Guthart provides stability and continuity in innovation and strategic execution.
Bear Case
High valuation multiples such as a trailing P/E of 53.76 and P/FCF of 64.35 make the stock sensitive to any slowdown in procedure growth or margin compression.
Competitive threats from emerging robotic surgery platforms and challenges in key markets like China could pressure market share and revenue growth.
Regulatory risks including reimbursement changes, anti-corruption scrutiny in China, and tariff impacts could negatively affect margins and system placements.
Macro uncertainties such as hospital spending constraints and government budget pressures in regions like Japan and the U.K. may slow adoption rates.
The company faces execution risks related to supply chain disruptions and tariff-related cost pressures, which have already contributed to a gross margin decline.
Leadership & Competitive Position
Dave Rosa
Tenure30 yrs
Beats guidance75% of qtrs
Capital allocationFair
Dave Rosa has been with Intuitive Surgical since 1996, progressing through engineering and leadership roles to CEO in 2025. He holds multiple patents and has overseen key growth initiatives including the da Vinci 5 launch. The prior CEO, Gary Guthart, served from 2010 to 2025 and transitioned to Executive Chair, bringing deep technical expertise and long-term strategic vision.
Intuitive Surgical holds over 60% market share in robotic-assisted surgery with approximately 10,000 da Vinci systems installed globally and nearly 17 million procedures performed by end-2024.
Competitors: Medtronic (MDT), Stryker (SYK)
Disruption: Medium due to emerging robotic platforms and competitive pressures in key markets like China.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
53.76x
68.8x
68.8x
52.9x
91.11x
P/S
15.15x
18.46x
18.32x
10.97x
22.0x
P/FCF
64.35x
81.77x
72.62x
39.76x
197.58x
P/S 15.15x vs 5yr range 10.97-22.0x (P25=15.12x, median=18.32x, P75=20.16x)
Continued global adoption of the da Vinci 5 system is expected to drive procedure volume growth and recurring revenue expansion.
high
2027-01-30
2026 Fiscal Year Earnings Release
Earnings results will provide clarity on margin recovery, procedure growth, and impact of tariffs and regulatory factors.
medium
2026-Q2
Regulatory Developments in China
Changes in anti-corruption enforcement and reimbursement policies in China could affect system placements and revenue growth.
medium
Risks
Valuation Sensitivity
high
High valuation multiples expose the stock to rapid derating if procedure growth slows or margins compress, with a trailing P/E of 53.76 and P/FCF of 64.35.
Competitive Pressure
medium
Emerging robotic surgery platforms and competition in key markets like China could erode market share and revenue growth.
Regulatory and Tariff Risks
medium
Regulatory challenges, anti-corruption scrutiny in China, and tariffs have already pressured margins by approximately 150 basis points and may continue to do so.
Macro Uncertainty
medium
Hospital spending constraints and government budget pressures in regions such as Japan and the U.K. may slow system adoption.
Execution and Supply Chain
medium
Supply chain disruptions and tariff-related cost increases pose ongoing risks to margin stability and growth execution.
Growth Engines
Da Vinci System Salesscaling
The da Vinci surgical system anchors a fast-growing minimally invasive surgery market with over 2.7 million procedures performed in 2024 and significant room for global expansion.
Recurring Instruments Revenuemature
Recurring revenue from instruments and accessories represents 85% of total revenue, driven by procedure volume growth and a large installed base.
Ion Robotic Bronchoscopyearly
Ion is a complementary robotic platform for lung biopsy with minimal current revenue contribution but potential for future growth.
The launch and adoption of the da Vinci 5 system have accelerated procedure volumes and recurring revenue growth, supporting strong top-line performance.
2025-12-31
FY 2025 Revenue Increases 21% to $10.1 Billion
Strong revenue growth reflects robust demand for robotic-assisted surgery and expansion of the installed base.
2025-09-30
China System Placements Lower Than Expected Due to Regulatory Challenges
Anti-corruption enforcement and policy issues in China have slowed system placements, highlighting execution risks in key international markets.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
What is ISRG's fair value?
QuantHub Research estimates ISRG's fair value at $1,039.74 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for ISRG?
Valuation Sensitivity: High valuation multiples expose the stock to rapid derating if procedure growth slows or margins compress, with a trailing P/E of 53.76 and P/FCF of 64.35. Competitive Pressure: Emerging robotic surgery platforms and competition in key markets like China could erode market share and revenue growth. Regulatory and Tariff Risks: Regulatory challenges, anti-corruption scrutiny in China, and tariffs have already pressured margins by approximately 150 basis points and may continue to do so.
What is the bull case for ISRG?
The da Vinci system maintains a dominant position with over 60% market share in robotic-assisted surgery and nearly 17 million procedures performed globally, supporting recurring revenue growth. Revenue grew 21% year-over-year in FY 2025, driven by strong adoption of the da Vinci 5 system and a 14-18% increase in procedure volumes, indicating robust demand. The company benefits from high gross margins of 66.3% and operating margins of 30.5%, reflecting operational efficiency and pricing power. F